Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.

Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE.

JCI Insight. 2018 May 17;3(10). pii: 99048. doi: 10.1172/jci.insight.99048. eCollection 2018 May 17.

2.

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A, Brito A, Sanchez JF, Ostberg JR, D'Apuzzo M, Badie B, Barish ME, Forman SJ.

Mol Ther. 2018 Jan 3;26(1):31-44. doi: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5.

3.

Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.

Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.

Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.

4.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B.

N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.

5.

L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.

Hong H, Brown CE, Ostberg JR, Priceman SJ, Chang WC, Weng L, Lin P, Wakabayashi MT, Jensen MC, Forman SJ.

PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.

6.

A role for the thermal environment in defining co-stimulation requirements for CD4(+) T cell activation.

Zynda ER, Grimm MJ, Yuan M, Zhong L, Mace TA, Capitano M, Ostberg JR, Lee KP, Pralle A, Repasky EA.

Cell Cycle. 2015;14(14):2340-54. doi: 10.1080/15384101.2015.1049782.

7.

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC.

Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9.

8.

Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.

Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, Chang WC, Bretzlaff W, Starr R, Priceman S, Ostberg JR, Forman SJ, Brown CE.

Mol Ther. 2015 Apr;23(4):757-68. doi: 10.1038/mt.2014.208. Epub 2014 Nov 4.

9.

Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.

Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

J Immunother. 2014 Feb-Mar;37(2):93-104. doi: 10.1097/CJI.0000000000000018.

PMID:
24509172
10.

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.

Blood. 2013 Oct 31;122(18):3138-48. doi: 10.1182/blood-2012-12-474056. Epub 2013 Sep 12.

11.

Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.

Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

PLoS One. 2013 Jun 6;8(6):e65519. doi: 10.1371/journal.pone.0065519. Print 2013.

12.

Tumor escape and progression under immune pressure.

Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR.

Clin Dev Immunol. 2012;2012:641079. doi: 10.1155/2012/641079. Epub 2012 Dec 19. No abstract available.

13.

Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC.

Gene Ther. 2013 Aug;20(8):853-60. doi: 10.1038/gt.2012.97. Epub 2013 Jan 10.

14.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

15.

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC.

Blood. 2011 Aug 4;118(5):1255-63. doi: 10.1182/blood-2011-02-337360. Epub 2011 Jun 7.

16.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19.

17.
18.

Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses.

Dayanc BE, Beachy SH, Ostberg JR, Repasky EA.

Int J Hyperthermia. 2008 Feb;24(1):41-56. doi: 10.1080/02656730701858297. Review.

PMID:
18214768
19.

Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.

Chang L, Chang WC, McNamara G, Aguilar B, Ostberg JR, Jensen MC.

Cytotherapy. 2007;9(8):771-84. Epub 2007 Oct 5.

PMID:
17917884
21.

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC.

Mol Ther. 2007 Apr;15(4):825-33. Epub 2007 Feb 13.

22.

Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I.

Nasirikenari M, Segal BH, Ostberg JR, Urbasic A, Lau JT.

Blood. 2006 Nov 15;108(10):3397-405. Epub 2006 Jul 18.

23.

An important role for granulocytes in the thermal regulation of colon tumor growth.

Ostberg JR, Ertel BR, Lanphere JA.

Immunol Invest. 2005;34(3):259-72.

24.

Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function.

Ostberg JR, Repasky EA.

Cancer Immunol Immunother. 2006 Mar;55(3):292-8. Epub 2005 Apr 28. Review.

25.

Protocols for simulating the thermal component of fever: preclinical and clinical experience.

Pritchard MT, Ostberg JR, Evans SS, Burd R, Kraybill W, Bull JM, Repasky EA.

Methods. 2004 Jan;32(1):54-62.

PMID:
14624878
26.

Thermal regulation of dendritic cell activation and migration from skin explants.

Ostberg JR, Kabingu E, Repasky EA.

Int J Hyperthermia. 2003 Sep-Oct;19(5):520-33.

PMID:
12944167
27.

Induction of stress proteins in a panel of mouse tissues by fever-range whole body hyperthermia.

Ostberg JR, Kaplan KC, Repasky EA.

Int J Hyperthermia. 2002 Nov-Dec;18(6):552-62.

PMID:
12537754
28.

A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models.

Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA.

Int J Hyperthermia. 2002 May-Jun;18(3):253-66.

PMID:
12028640
29.
30.

Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules.

Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, Repasky EA.

Blood. 2001 May 1;97(9):2727-33.

PMID:
11313264
31.
32.

Regulatory effects of fever-range whole-body hyperthermia on the LPS-induced acute inflammatory response.

Ostberg JR, Taylor SL, Baumann H, Repasky EA.

J Leukoc Biol. 2000 Dec;68(6):815-20.

PMID:
11129648
33.

Use of mild, whole body hyperthermia in cancer therapy.

Ostberg JR, Repasky EA.

Immunol Invest. 2000 May;29(2):139-42. No abstract available.

PMID:
10854182
34.
35.
36.

The Roman god Janus: a paradigm for the function of CD43.

Ostberg JR, Barth RK, Frelinger JG.

Immunol Today. 1998 Dec;19(12):546-50. Review. No abstract available.

PMID:
9864944
37.

Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens.

Ostberg JR, Dragone LL, Borrello MA, Phipps RP, Barth RK, Frelinger JG.

Eur J Immunol. 1997 Sep;27(9):2152-9.

PMID:
9341753
38.

Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency.

Ostberg JR, Dragone LL, Driskell T, Moynihan JA, Phipps R, Barth RK, Frelinger JG.

J Immunol. 1996 Dec 1;157(11):4876-84.

PMID:
8943391

Supplemental Content

Loading ...
Support Center